RET and medullary thyroid gland carcinoma: These results, together with the evidence that MTC has a low rate of mutations other than RET, explains the relatively moderate level of aggressiveness of the disease with respect to other, more aggressive tumors (lung adenocarcinoma or melanoma) that are characterized by a high rate of mutation and heterogeneity.